Alzheimer’s Disease Pipeline Insight Report 2023

DelveInsight’s “Alzheimer’s Disease Pipeline Insight 2023” report provides comprehensive insights about key companies and pipeline drugs in the Alzheimer’s Disease pipeline landscapes. 

The report comprises Alzheimer’s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer’s Disease pipeline products.     

Alzheimer’s Disease Overview

Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.

Alzheimer’s disease is a disease whose precise causes are unknown. However, at a fundamental stage, brain proteins malfunction, disrupting the work of brain cells (neurons) and triggering a cascade of toxic events. Neurons become weakened, lose their ties, and ultimately die.

Some of the key takeaways from the Alzheimer’s Disease Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme, Otsuka Pharmaceutical, etc., are developing therapies for the treatment of Alzheimer’s Disease.
• Emerging therapies such as Lecanemab (BAN2401), Aducanumab (BIIB037), Gantenerumab, Atuzaginstat (COR388), Brexpiprazole, are expected to have a significant impact on the  Alzheimer’s Disease market in the coming years.

Get an overview of pipeline landscape @ Alzheimer’s Disease Clinical Trials Analysis

Alzheimer’s Disease Pipeline Therapies along with Key Players:

• Lecanemab (BAN2401): Eisai/BioArctic AB
• Aducanumab (BIIB037): Biogen 
• Gantenerumab: Hoffmann-La Roche
• Atuzaginstat (COR388): Cortexyme 
• Brexpiprazole: Otsuka Pharmaceutical

Scope of Alzheimer’s Disease Pipeline Drug Insight

• Coverage: Global 
• Major Players: Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme, Otsuka Pharmaceutical, and others.
• Pipeline Therapies:  Lecanemab (BAN2401), Aducanumab (BIIB037), Gantenerumab, Atuzaginstat (COR388), Brexpiprazole, and others.

Table of Contents

Related Reports:

Alzheimer’s Disease Market

DelveInsight’s ‘Alzheimer’s Disease-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Alzheimer’s Disease Epidemiology

DelveInsight’s ‘Alzheimer’s Disease Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/